source
- Moderna and Merck's mRNA cancer vaccine extends survival in phase 3 melanoma trialMerck and Moderna reported that their personalized mRNA cancer vaccine improved patient outcomes in a late-stage study. The phase 3 INTerpath-001 trial enrolled 1,137 patients who had surgery to r…
- Novartis and BMS pause CAR-T trials after fatal immune syndrome casesNovartis has halted several immunology and neurology studies of its CAR T candidate rapcabtagene autoleucel after three patients experienced fatal immune effector cell‑associated hemophagocytic syn…